Predicting outcome of lithium added to antidepressants in resistant depression (Q39457879)

12 September 2017

title

Predicting outcome of lithium added to antidepressants in resistant depression (English)

1 reference

12 September 2017

Alvarez E

1

1 reference

12 September 2017

Pérez-Solá V

2

1 reference

12 September 2017

Pérez-Blanco J

3

1 reference

12 September 2017

Queraltó JM

4

1 reference

12 September 2017

Torrubia R

5

1 reference

12 September 2017

Noguera R

6

1 reference

12 September 2017

publication date

1 February 1997

1 reference

Journal of Affective Disorders

12 September 2017

published in

1 reference

12 September 2017

volume

42

1 reference

12 September 2017

issue

2-3

1 reference

12 September 2017

page(s)

179-186

1 reference

Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake Inhibitors

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium Augmentation in Antidepressant-Resistant Patients a Quantitative Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium carbonate and L-tryptophan in the treatment of bipolar and schizoaffective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Behavioral and biochemical changes induced by lithium and l-tryptophan in muricidal rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Predictors of response to amine-specific antidepressants.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Prediction of outcome in depressive illness by the Newcastle Diagnosis Scale. Its relationship with the unipolar/bipolar and DSM-III systems

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Potentiation of lithium by tryptophan in a patient with bipolar illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Clinical implications of imipramine plasma levels for depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Mood response to methylphenidate and the Dexamethasone Suppression Test as predictors of treatment response to zimelidine and lithium in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

The benefit of lithium carbonate adjunct in refractory depression--fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium augmentation in psychotic depression refractory to combined drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Refractory depression: the addition of lithium to fluoxetine or desipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

POTENTIATION OF MONOAMINE-OXIDASE INHIBITORS BY TRYPTOPHAN

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Possible synergism between fluoxetine and lithium in refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Variability of response to lithium augmentation in refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

The DST as a predictor of outcome in depression: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium potentiation of imipramine in treatment resistant depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Psychobiological predictors of antidepressant drug response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

A potential clinical use for methylphenidate with tricyclic antidepressants.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2896%2901407-3

7 January 2021

10.1016/S0165-0327(96)01407-3

Identifiers

DOI

1 reference

12 September 2017

1 reference